Dermatology

August 5th 2025

The efficacy and safety of both approved and investigational drugs for moderate to severe hidradenitis suppurativa offer valuable evidence to guide clinical decision-making in a field where head-to-head trials are largely absent.

July 24th 2025

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

July 22nd 2025

The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.

July 2nd 2025

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.